Table 1. – Characteristics of Patients with (Group A) and without (Group B) Sildenafil Pre-Treatment Before Heart Transplant.
| Characteristica | Group A (n=30) | Group B (n = 205) | p-valueb |
|---|---|---|---|
| Mean Age, years | 53.6 ± 10.9 | 52.9 ± 13.4 | 0.545 |
| Gender Male, % | 86.7 | 76.2 | 0.247 |
| Etiology | |||
| Ischemic, % | 50.0 | 34.0 | 0.346 |
| Idiopathic, % | 36.7 | 56.3 | |
| Hypertrophic, % | 3.3 | 4.4 | |
| Restrictive, % | 10.0 | 2.9 | |
| Congenital, % | 0.0 | 2.4 | |
| NYHA Class | |||
| III, % | 33.3 | 36.4 | 0.968 |
| IV, % | 66.7 | 63.6 | |
| Laboratorial Parameters | |||
| Hemoglobin, g/dl | 12.3 ± 1.8 | 12.7 ± 1.7 | 0.815 |
| Creatinine, mg/dl | 1.4 ± 1.0 | 1.3 ± 0.5 | 0.060 |
| BNP, pg/ml | 524 [396 - 912] | 625 [306 - 1039] | 0.906 |
| Cardiac Parameters | |||
| LVEF, % | 19.6 ± 4.5 | 21.2 ± 8.4 | 0.021 |
| Mitral Regurgitation | |||
| Mild, % | 16.0 | 12.5 | 0.703 |
| Moderate, % | 32.0 | 34.0 | |
| Moderate-Severe, % | 24.0 | 14.6 | |
| Severe, % | 24.0 | 31.2 | |
| Cardiac Devices | |||
| ICD, % | 40.0 | 21.8 | 0.128 |
| CRT, % | 10.0 | 22.4 | |
| Sildenafil, pre-HTx | |||
| Duration, days | 65 [4 – 181] |
BNP: blood natriuretic peptide; CRT: cardiac resynchronization therapy; HT: heart transplant; ICD: implantable cardioverter defibrillator; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association. aData are expressed as percentages, mean ± standard deviation or median (interquartile range). bStudent`s T-test for continuous variables with normal distribution, Mann-Whitney test for continuous variables without normal distribution and Chi-Square test for categorical variables.